Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This analysis estimates clinical eligibility and use of GLP-1 drugs among adults under age 65 in the private and employer-sponsored insurance (ESI) markets using the 2023 National Health Interview Survey (NHIS) and Merative MarketScan commercial claims data
Some of the conditions that they treat include depression, substance abuse and anxiety disorders
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
Availability: 210 in stock
Half of the patients received the GLP-1 agonist medication, and the other half received a placebo, with a mix of those also taking buprenorphine and not taking it in each group
Only $80 for a 500mL bag
Continuous data that was not reported as mean and standard deviation (SD) was converted to this format using the Meta-Analysis Accelerator website [26]
US$ 27.58
US$ 22.04
US$ 26.57
US$ 22.96
US$ 28.44
